{
  "abstract": "Background CD24 is a heavily glycosylated glycosylphosphatidylinositol (GPI)-anchored protein expressed on the surface of many cell types including cancer cells. It is overexpressed in many cancer types and is known to serve as a ‘don’t eat me’ signal to macrophages through its engagement of the inhibitory receptor Siglec-10. 1 Methods We analyzed CD24 copy number, mRNA and clinical data across all indications in The Cancer Genome Atlas (TCGA). We also analyzed CD24 copy number and mRNA of all cell lines in DepMap.Results We found that CD24 copy number gain is most frequently observed in ovarian cancer, sarcomas, and non-seminomatous germ cell tumors (>30% of tumors showed CD24 gain); followed by endometrial, colorectal, and miscellaneous neuroepithelial cancers (>24%). CD24 copy number correlates to mRNA in many cancer types. CD24 gain is significantly associated with poor overall survival in breast, 2 cholangiocarcinoma, endometrial, esophagogastric, glioma, and renal cancers. CD24 gain is prevalent in the uterine carcinosarcoma subtype of endometrial cancers (59% vs. 24% overall) and basal-like subtype of breast cancers (47% vs. 21% overall). Small cell lung cancer (SCLC) is an aggressive cancer with limited biopsies thus it is absent in TCGA. We analyzed all 1,925 cancer cell lines in DepMap and found that CD24 gain is frequent in SCLC lines over non-small cell lung cancer (NSCLC) or other non-lung cancer cell lines. CD24 copy number status also significantly correlates with mRNA in SCLC lines.Conclusions Taken together, CD24 gene amplification status could serve as a potential biomarker and prognostic factor across various cancer indications.References Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392–6.Zhang P, Zheng P and Liu Y. Amplification of the CD24 gene is an independent predictor for poor prognosis of breast cancer. Frontiers in Genetics. 2019;10:560.",
  "authors": [
    {
      "affiliations": [
        "Pheast Therapeutics, Redwood City, CA, USA"
      ],
      "name": "Jennifer Yinuo Cao"
    },
    {
      "affiliations": [
        "Pheast Therapeutics, Redwood City, CA, USA"
      ],
      "name": "Josie L Hayes"
    },
    {
      "affiliations": [
        "Pheast Therapeutics, Redwood City, CA, USA"
      ],
      "name": "Joshua D Rudolph"
    },
    {
      "affiliations": [
        "Pheast Therapeutics, Redwood City, CA, USA"
      ],
      "name": "Giovanni C Forcina"
    },
    {
      "affiliations": [
        "Pheast Therapeutics, Redwood City, CA, USA"
      ],
      "name": "Kelsey E Hart"
    },
    {
      "affiliations": [
        "Pheast Therapeutics, Redwood City, CA, USA"
      ],
      "name": "Roy L Maute"
    }
  ],
  "title": "1226 CD24 gene amplification associates with poor survival outcomes across cancer indications",
  "uid": "ab0e1d76-4d7d-5607-aaed-bd975e9e95d3"
}